Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting...
-
Upload
gwendoline-gallagher -
Category
Documents
-
view
213 -
download
0
Transcript of Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting...
![Page 1: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/1.jpg)
Toxicological Emergencies in the Oncology Patient: Antidotal Therapies
2008 ACMT Pre-Meeting Symposium
Rama B. Rao, MD
NYCPCC
NYPH-Weill-Cornell Medical Center
![Page 2: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/2.jpg)
Methotrexate and Carboxypeptidase G2
GLUCARPIDASE
![Page 3: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/3.jpg)
N5,N10-Methylene-THF N5-Methyl-THFN10-Formyl-THF
dTMP(DNA synthesis)
S-Adenosylmethionine(Methylation of proteins,
lipids, RNA and DNA)
IMP(purines
de novo synthesis)
dUMPHomo-
cysteine
Dihydrofolatereductase (DHFR)
Folate Tetrahydrofolate (THF)
FOLATE METABOLISM
![Page 4: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/4.jpg)
N5,N10-Methylene-THF N5-Methyl-THFN10-Formyl-THF
dTMP(DNA synthesis)
S-Adenosylmethionine(Methylation of proteins,
lipids, RNA and DNA)
IMP(purines
de novo synthesis)
dUMPHomo-
cysteine
Methotrexate
Dihydrofolatereductase (DHFR)
Folate Tetrahydrofolate (THF)
![Page 5: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/5.jpg)
Methotrexate
• Neoplasms• Fetal cells• Disorders of
– Immune system– Rheumatology– Dermatology
![Page 6: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/6.jpg)
Methotrexate Toxicity
Scheinfeld N. Three cases of toxic skin eruptions associated with methotrexate…Derm Online Journal 2006;12(7):15.
Not for publication. For educational use only.
![Page 7: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/7.jpg)
Systemic Methotrexate Toxicity
• Mucositis, stomatitis• Dermatitis• GI distress• Hematologic/Immuno-
suppression• Organ dysfunction
– Hepatitis– Pulmonary – Renal
Scheinfeld N. Derm Online Journal 2006;12(7):15.
Not for publication. For educational use only.
![Page 8: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/8.jpg)
Risk Factors: MTX Toxicity
• Renal Impairment– Medication interactions– Failure
• Overdose
• Idiosyncratic:– Wide differences in concentrations with
administration of 1 gm/m2 IV Smith S, et al. J Med Tox 2008;4(2):132-140; Evans WE, et al. Clinical pharmacodynamics of high dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect. New Engl J Med 1986;314(8):471-477.
![Page 9: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/9.jpg)
Identifying Systemic Methotrexate Toxicity
• Known overdose
• Therapeutic monitoring plasma levels:– Therapeutic < 1 M/L at 48 hours – Toxicity > 1 M/L at 48 hours
> 10 M/L at 24 hours
• Clinical findings: Manifest over a few daysWang 2006, Howland 2006
![Page 10: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/10.jpg)
Decrease MTX
Concentrations
Bypass inhibitedpathways
Leucovorin
NaHCO3
Invasive therapy
Infectiousvigilance1
HydrationGCSF
Supportive
1. Moisa 2006
![Page 11: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/11.jpg)
Decrease MTX
Concentrations
Bypass inhibitedpathways
Leucovorin Dose to ≥ MTX plasma concentration 100 mg/m2 IV Q 6 hours NEVER INTRATHECALLY Continue treatment in severely ill patients until there is evidence of
recovery
NaHCO3
Invasive therapy
InfectiousvigilanceHydrationGCSF
Supportive
![Page 12: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/12.jpg)
Mechanism of methotrexate
N5,N10-Methylene-THF N5-Methyl-THFN10-Formyl-THF
dTMP(DNA synthesis)
S-Adenosylmethionine(Methylation of proteins,
lipids, RNA and DNA)
IMP(purines
de novo synthesis)
dUMPHomo-
cysteine
Methotrexate
Dihydrofolatereductase (DHFR)
Folate Tetrahydrofolate (THF)
![Page 13: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/13.jpg)
Decrease MTX
Concentrations
Bypass inhibitedpathways
Leucovorin
NaHCO3
Enhances solubility
InfectiousvigilanceHydrationGCSF
Supportive
![Page 14: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/14.jpg)
Decrease MTX
Concentrations
Bypass inhibitedpathways
Leucovorin
NaHCO3
Invasive therapy HD/HP
InfectiousvigilanceHydrationGCSF
Supportive
![Page 15: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/15.jpg)
Decrease MTX
Concentrations
Bypass inhibitedpathways
Leucovorin
NaHCO3
Invasive therapy
InfectiousvigilanceHydrationGCSF
Supportive
GLUCARPIDASE
![Page 16: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/16.jpg)
Glucarpidase (CPDG2)
• FDA approved as single use Investigational New Drug for compassionate therapy
• Dosing for systemic methotrexate toxicity– 50 u/kg IV over 5 minutes
• 70 patients reduction of methotrexate concentrations by 98% at 15 minutes
• Adverse events in 329 patients: – Flushing, hypersensitivity, pruritis– HTN, dysrhythmias?
Package Insert Glucarpidase, O’Marcaigh 1996. Schwartz S et al.Oncologist 2007; 12:1299-1308; Snyder 2007
![Page 17: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/17.jpg)
Glutamate
Methotrexate
OH
DAMPA
GLUCARPIDASE
![Page 18: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/18.jpg)
Glucarpidase Limitations
• DAMPA – Low solubility in urine
• Continue alkalinization of urine
– Affects methotrexate assays• Use HPLC post treatment to follow MTX
• Cleaves leucovorin– Allow 2-4 hour interval between medications– Current investigation– Continue therapy for 48 hours after glucarpidase
• Availability: HD/HP while awaiting
Schwartz S et al.Oncologist 2007; 12:1299-1308
![Page 19: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/19.jpg)
Glucarpidase Limitations
• DAMPA – Low solubility in urine
• Continue alkalinization of urine
– Affects methotrexate assays• Use HPLC post treatment to follow MTX
• Cleaves leucovorin– Allow 2-4 hour interval between medications– Current investigation– Continue therapy for 48 hours after glucarpidase
• Availability: HD/HP while awaiting
Schwartz S et al.Oncologist 2007; 12:1299-1308
![Page 20: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/20.jpg)
IV Glucarpidase Indications
• Advanced signs of clinical toxicity
• Persistently elevated MTX concentrations
• Clcr ≤ 60 mL/min/m2
• Patient with a combination of:– Renal failure– On leucovorin– Plasma MTX concentration > 10M/L at 24
hours
Package insert. Widemann 2004.
![Page 21: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/21.jpg)
Intrathecal Methotrexate Toxicity
![Page 22: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/22.jpg)
CSF Methotrexate Toxicity
• Within 60 minutes to a few hours– Headache– Vomiting – Altered mentation– Seizure– Apnea– CV instability– Death
Ettinger 1985;Jakobson 1992,Finkelstein 2004
![Page 23: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/23.jpg)
Decrease MTX
Concentrations
Bypass inhibitedpathways
Leucovorin IV
IV NaHCO3
Invasive therapy CSF drainage/ irrigation/perfusion
InfectiousvigilanceHydrationGCSF
Supportive
![Page 24: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/24.jpg)
CSF Drainage
• Remove up to 94% of MTX if drainage occurs within first 15 minutes
• Diminishes to 30-40% if performed at 2 hours
Riva 1999, O’Marcaigh 1996, Jakobson 1992, Widemann 2004.
![Page 25: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/25.jpg)
Decrease MTX
Concentrations
Bypass inhibitedpathways
Leucovorin IV
IV NaHCO3
Invasive therapy CSF drainage/ irrigation/perfusionIT GLUCARPIDASE
InfectiousvigilanceHydrationGCSF
Supportive
![Page 26: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/26.jpg)
Intrathecal Glucarpidase
• Non-human primate model of intrathecal MTX overdose– 400 fold decrease in CSF concentrations
within 5 minutes of administration
• No primate deaths
Adamson 1991
![Page 27: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/27.jpg)
Intrathecal Glucarpidase
• Human data– 7 patients 155 mg – 600 mg MTX– Included 4 children ages 5-9– All received:
• Drainage (some with perfusion)• Intravenous Leucovorin• Intrathecal Glucarpidase within 5 hours
Widemann 2004
![Page 28: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/28.jpg)
Indications?
• May depend on intrathecal MTX dosage and symtoms:– Less than 100 mg: many adults will respond
well to drainage and IV leucovorin alone– Between 100 mg and 500 mg MTX have
variable outcomes – One survivor of 1200 mg IT MTX without
glucarpidase
![Page 29: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/29.jpg)
Consider IT Glucarpidase
• Severe CNS symptoms• Consider when dosage of MTX is > 100
mg• Ideal patient is yet to be defined
• Dosing: 2 vials IT (1000 units/vial) standard for adults or children after initial drainage
![Page 30: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/30.jpg)
IV/IT Glucarpidase
• Adjunctive therapy in methotrexate overdose
• May obviate the need for:– HD/HP in systemic toxicity– Ventricular-lumbar perfusion in IT toxicity
• Prevention is key
![Page 31: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/31.jpg)
DEXRAZOXANE
![Page 32: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/32.jpg)
Extravasations of Chemotherapy
1. NEIS 2. Schulmeister 3. Sauerland
Not for publication. For educational use only.
1.
2.
3.
![Page 33: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/33.jpg)
Chemotherapy Extravasations
• Incidence – 0.1- 6%– Unknown for intrathoracic
• Retrospective study at a major cancer center– <0.01%
Sauerland 2006, Khan 2002, Langenstein 2002
![Page 34: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/34.jpg)
Chemotherapy Extravasations
• Recent prospective study, 36 centers in 5 countries in Europe
– Time period and total number of administrations not reported
– 80 potential extravasation cases
Mouridsen 2007
![Page 35: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/35.jpg)
Natural History
• Fullness, induration• Resistance to flushing the line• Pain• Redness• Blistering• Discoloration• Necrosis• Full thickness skin loss
Kretschmar 2006, Stein 1997, Mayo 1998, Loth 1991, Eom 2005, Linder 1985
![Page 36: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/36.jpg)
Chemotherapy Classification
• Irritants
• Vesicants
![Page 37: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/37.jpg)
Irritants
Class ExamplesAlkylating agents Carmustine, ifosfamide
Platinum analogs Carboplatin, cisplatin
Topoisomerase II inhibitors Etoposide
? Liposomal anthracyclines
Goolsby 2006, Schrijvers 2003, Wang 2006, NEIS discussion forum
![Page 38: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/38.jpg)
OxaliplatinKretzschmar A. Clin Onc 2003;21(21):4068-4069
Not for publication. For educational use only.
Irritant
Wood LS Am J Nursing 1993
![Page 39: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/39.jpg)
Vesicants
• Non DNA-binding
• DNA binding
Goolsby 2006, Schrijvers 2003, Wang 2006
![Page 40: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/40.jpg)
Non-DNA Binding Vesicants
Class ExampleVinca alkaloids Vincristine, vinblastine
Taxane Paclitaxel
Non-classical
alkylator Amsacrine
Goolsby 2006, Schrijvers 2003, Wang 2006
![Page 41: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/41.jpg)
DoxcetaxelEl Saghir NS. Anticancer Drugs
2004;15:401-404.Not for publication. For educational use only.
Non-DNA Binding Vesicants
![Page 42: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/42.jpg)
VinblastineViale PH. Sem Onc Nuring 2006;22(3):144-151.
Not for publication. For educational use only.
Non-DNA Binding Vesicants
![Page 43: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/43.jpg)
DNA Binding Vesicants
Class Examples
Alkylating agents Mechlorethamine
Antitumor antibiotics Dactinomycin
Anthracyclines Doxorubicin, daunorubicin
![Page 44: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/44.jpg)
Eom YW. Oncogene 2005;24:2765Not for publication. Educational use only.
Doxorubicin effects on human hepatoma cells.
![Page 45: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/45.jpg)
Mechanism DNA Binding Vesicants
• Enter nucleus• Bind nucleic acids
– Inhibit topoisomerase II– Precipitate multiple DNA strand breaks– Free radical formation through
• Semiquinones• Iron
• Apoptosis/mitotic catastrophe Re-release
Schulmeister 2007, Sauerland 2006, Eom 2005
![Page 46: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/46.jpg)
DNA Binding Vesicants
Sauerland C. Onc Nursing Forum 2006Not for publication. For educational use only.
![Page 47: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/47.jpg)
Doxorubicin Extravasation
Courtesy of Lisa SchulmeisterNot for publication. For educational use only.
![Page 48: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/48.jpg)
Liposomal Doxorubicin
Courtesy of Lisa SchulmeisterNot for Publication. For educational use only.
![Page 49: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/49.jpg)
Oncology Nursing Society
• Strongly urges training of providers administering anti-neoplastic agents
• Major cancer centers have similar, if not identical guidelines
![Page 50: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/50.jpg)
Risk Factors for Extravasation
• Untrained personnel– 33/38 extravasations during administration
by housestaff, faculty physicians or substitute nurses
Linder 1985
![Page 51: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/51.jpg)
DNA Binding Vesicants
D’Andrea Scand J Plast Recon Surg 2004.Not for publication. For educational use only.
![Page 52: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/52.jpg)
DNA Binding Vesicants
D’Andrea Scand J Plast Recon Surg 2004.Not for publication. For educational use only.
![Page 53: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/53.jpg)
Training
• Selection/assessment of access site– Order and placement of peripheral attempts
• Checklists:– Tourniquet removal– Patient education– Assessment
• Central lines, infusion pumps, bolus dosing
• Response to patient complaints• Assumption of extravasation when in doubt
Schulmeister 2006, Sauerland 2006
![Page 54: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/54.jpg)
Training
• Selection/assessment of access site– Order and placement of peripheral attempts
• Checklists:– Tourniquet removal– Patient education– Assessment
• Central lines, infusion pumps, bolus dosing
• Response to patient complaints• Assumption of extravasation when in
doubtSchulmeister 2006, Sauerland 2006
![Page 55: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/55.jpg)
DNA Binding Vesicants
Doxorubicin extravasation.Rudolph R. J Clin Onc 1987.
Not for publication. For educational use only.
![Page 56: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/56.jpg)
Less Preventable Risk Factors
• Sudden movement from vomiting
• Use of agents that cause sedation
• Patient co-morbidities or prior sequelae from chemotherapy
• Proximal scarring or thrombosis
Schulmeister 2006, Sauerland 2006, Mayo 1998
![Page 57: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/57.jpg)
Central Line Risk Factors
• Catheter migration or fracture• Multiple attempts• Perforation of vessel
Mayo 1998, Bozkurt 2003, Anderson 1996, Krasna 1991, Kassner 2000, Durhsen 1997, Crues 2002, Lokich 1999, Leong 1996
![Page 58: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/58.jpg)
Intrathoracic Extravasations
• Mediastinitis• Effusions
– Pleural– Pericardial
• Phrenic nerve palsy• Protracted cough• Fatality
Mayo 1998, Bozkurt 2003, Anderson 1996, Krasna 1991, Kassner 2000, Durhsen 1997, Crues 2002, Lokich 1999, Leong 1996; Schulmeister L. A complication of vascular access device insertion. J Intravenous Nursing 1998;21:197-202.
![Page 59: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/59.jpg)
Chest Wall Extravasation
• Extrusion from venotomy site
• Inadequate placement of line in relation to SVC
• Fibrin sheath formation
Mayo 1998, Bozkurt 2003, Anderson 1996, Krasna 1991, Kassner 2000, Durhsen 1997, Crues 2002, Lokich 1999, Leong 1996
![Page 60: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/60.jpg)
Fibrin Sheath Formation
Mayo DJ. Supp Care Cancer 1998.Not for publication. For educational use only.
![Page 61: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/61.jpg)
Doxorubicin extravasation with neuropathy at 2 months.Disa JJ et al. 1998
Not for publication. For educational use only.
![Page 62: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/62.jpg)
Extremity Extravavasations:Clinical Consequences
• Prolonged morbidity• Multiple surgeries• Septicemia• Poor mobility• Delay of
chemotherapy• Compartment
syndrome
• Contractures• Scarring• Lymphedema• Recall reactions• Chronic pain• Quality of life issues
Kumar 2001, Linder 1985, Sauerland 2006, Anderson 1996, Bozkurt 2003, Durhsen 1997,Quintanar Verdugues 2008
![Page 63: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/63.jpg)
Consequence or Coincidence?
• A patient survives early diagnosis of adenocarcinoma of stomach
• Tumor formation on the dorsum of her hand which was diagnosed as squamous cell carcinoma
Lauvin 1995
![Page 64: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/64.jpg)
• The site of extravasation of doxorubicin ten years prior
• Lymph node metastases
• Patient died within 16 months of diagnosis
Consequence or Coincidence?
1Lauvin 1995
![Page 65: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/65.jpg)
ExtravasationDifferential Diagnosis
• Flare reaction– Local irritation– Streaking– Phlebitis
• Recall reaction
Wood 1993, Cox 1984, Wickham 2006, Valencak 2007, Saini 2006, Susser 1999, Shapiro 1994, Schulmeister 2006
![Page 66: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/66.jpg)
Recall Reaction
• Proper intravenous administration causes irritation, swelling and even blistering at a remote site of previous:
– Radiation– Extravasation of the same agent
• Can occur weeks to years after initial injury
Wood 1993, Cox 1984, Wickham 2006, Valencak 2007, Saini 2006, Susser 1999, Shapiro 1994, Schulmeister 2006, Du Bois 1996
![Page 67: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/67.jpg)
Saini A. Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug
extravasation. Lancet Oncol 2006;7:186-187.Not for publication. For educational use only.
![Page 68: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/68.jpg)
Management Extravasations
![Page 69: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/69.jpg)
Initial Management
• Leave access in place and attempt to withdraw any extravasant
• Debate regarding flushing the area with saline– Recommended for intrathoracic
extravasations
• Remove line
![Page 70: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/70.jpg)
Conundrum: Anthracyclines
• Most of the event is subcutaneous
• Injury is delayed
• Outcome can be severe with up to 33% tissue necrosis
Kretschmar 2006, Stein 1997, Mayo 1998, Loth 1991, Eom 2005, Linder 1985
![Page 71: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/71.jpg)
Options for Anthracycline Extravastions
• Wait and watch– Persistent pain after 2 weeks– OR for resection of necrotic tissue– Disadvantage:
• Waiting for necrosis• May require prolonged hospitalization or
revisitations • Some re-opening and debridement thereafter not
uncommon
– Advantage: • Some will recover without requiring resection
![Page 72: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/72.jpg)
Option: Anthracycline Extravasation
• Aggressive Surgery– Assume the evolution of necrosis will occur– Perform wide excision early to avoid
progression
• Advantage: prevent the pain and debilitation of necrosed tissue
• Disadvantage: Invasive, not always necessary
![Page 73: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/73.jpg)
Identifying Injured Tissue
• Anthracyclines bind to nucleic acids
• Can be identified by fluorescence microscopy of biopsy specimens1
• Negative specimens did not develop necrosis2
Dahlstrom1 1990; Andersson2 AP et al. 1993.
![Page 74: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/74.jpg)
Intermediate Therapy
• Fluoresence microscopy of biopsy specimens
• Resection of positive specimens
• Disadvantage: Still invasive
Mouridsen 2007, Andersson 1993, Schulmeister 2007, Scott Ely, MD Personal communication.
![Page 75: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/75.jpg)
Dexrazoxane
Vd = 22 - 36 L/m2
Distribution in total body water.
42% elimination in urine
No protein binding
![Page 76: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/76.jpg)
Dexrazoxane
• FDA Approved September 2007 for extravasations of anthracyclines
• Previously approved by FDA for use of limiting cardiotoxicity from anthracyclines in patients with >300 mg/m2 cumulative dose
Schucter 2002, Schulmeister 2008
![Page 77: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/77.jpg)
DEXRAZOXANE
Schulmeister 2008, Langer 2000
![Page 78: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/78.jpg)
![Page 79: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/79.jpg)
Dexrazoxane Metabolism
Dexrazoxane Fe bindingmetabolite
Hasinoff BB. 2008;17(2):21-233
![Page 80: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/80.jpg)
Mechanism Anthracycline Injury
• Enter nucleus• Bind nucleic acids
– Inhibit topoisomerase II– Precipitate multiple DNA strand breaks
– Free radical formation through • Semiquinones• Iron
• Apoptosis/mitotic catastrophe Re-release
Schulmeister 2007, Sauerland 2006, Eom 2005
![Page 81: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/81.jpg)
Animal Model: Dexrazoxane
• Mice receive SC administration of an anthracycline (AC) or H2O2 or saline
• Followed by systemic dexrazoxane
• Reduction of tissue lesions of AC
• No reduction of H2O2 lesions
Langer 2000
![Page 82: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/82.jpg)
Dexrazoxane in Humans
• Sporadic case reports – Epirubicin– Doxorubicin
– No surgeries– Some delay to therapy
Langer 2000 (letter), Bos 2001, Jensen 2003 Frost 2006, El Saghir 2004, Uges 2006
Bos AM, et al., Acta Oncologica 2001.Not for publication. For educational use only.
POST USE DEZRAZOXANE
![Page 83: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/83.jpg)
Dexrazoxane: Prospective Study
• Prospective multi-center, multi-country
• Well defined criteria for enrollment
• Sequential observation, single arm, open label
• Administration of dexrazoxane not delayed
• Outcome measures: decrease in surgeries
Mouridsen 2007
![Page 84: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/84.jpg)
Dexrazoxane Study Results
• 80 patients identified
• 53 of 54 were assessable
• Reduction in surgery at one arm of study by 100%
• Only one patient required surgery
Mouridsen 2007
![Page 85: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/85.jpg)
Dexrazoxane Study: Adverse Events
• Pain at infusion site
• Nausea, vomiting up to 18.8% in one wing
• Wound infections
• Transient elevations in LFTs
Mouridsen 2007
![Page 86: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/86.jpg)
Dexrazoxane Study Limits
• Relation to makers of dexrazoxane
• Design might by default reduce surgeries in some places where immediate surgical evaluation was standard. (single armed investigation)
• Design might enhance vigilance and limit extent of injury
Mouridsen 2007
![Page 87: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/87.jpg)
Strengths
• Well defined criteria for injury– Study Size– Diagnosis
• Clinically relevant, biopsy proven exposures
– 4 patients had intrathoracic extravasations
Mouridsen 2007
![Page 88: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/88.jpg)
Dexrazoxane for Extravasation
• Administered < 6 hours of extravasation– 1000 mg/m2 IV first dose over 2 hours not to exceed 2000
mg– 1000 mg/m2 IV at 24 hours over 1-2 hours, max 2000 mg– 500 mg/m2 IV at 48 hours over 1-2 hours, max 1000 mg
• Adjust in creatinine clearance administering 50% of the above doses for CLCR < 40 mL/min – Urinary excretion 42%
Hasinoff 2008, Package Insert Dexrazoxane
![Page 89: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/89.jpg)
Dexrazoxane
• Three makers in USA– Generic – Patent holders for prevention of cardiotoxicity
– Patent holders for extravasation
• Dosing is higher for extravasations than for prevention of cardiotoxicity
American Society of Health Systems Pharmacists 25 August 2008
![Page 90: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/90.jpg)
Dexrazoxane
• Three makers in USA– Generic Unknown Cost. Available September 2008
– Patent holders for prevention of cardiotoxicity $513.08 for 500 mL of reconstituted solution Available November 2008
– Patent holders for extravasation $14,750
• Dosing is higher for extravasations than for prevention of cardiotoxicity
American Society of Health Systems Pharmacists 25 August 2008
![Page 91: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/91.jpg)
Dexrazoxane
• Adverse events– Nausea, vomiting, LFT abnormalities,
myelosuppression, phlebitis
• Contraindications– Pregnant/nursing/children?
• No concomitant use of topical DMSO – Based on animal model
• No data on buffering
Hasinoff 2008; Hooke MC. J Ped Onc Nursing 2005;22:261-264 Lipshultz SE, et al. The effect of dexrazoxane on myocardial injury. New Engl J Med 2004;351:145-152.
![Page 92: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/92.jpg)
Jensen JN. Dexrazoxane – a promising antidote in the treatment of accidental extravasation of anthracyclines. Scand J Plastic and Recon
Sur Hand Surg 2003;37:3:174-175.Not for publication. For educational use only.
![Page 93: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/93.jpg)
Outstanding Questions
• Role in liposomal extravasations
• If/When to administer to children and at what dosing
• Need for biopsy?
• Role in intrathoracic extravasationsHooke MC. J Ped Onc Nursing 2005;22:261-264., Lipshultz SE, et al. The effect of dexrazoxane on myocardial injury. New Engl J Med 2004;351:145-152
![Page 94: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/94.jpg)
Summary• Prevention is key• Fluorescence microscopy
should be the gold standard for identifying at-risk tissue
• Further evaluations of the safety and utility of dexrazoxane are indicated
• The current data is promising Bos AM, et al., Acta Oncologica 2001.
Not for publication. For educational use only.POST USE DEZRAZOXANE
![Page 95: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/95.jpg)
Disclosure/Information• I have no financial conflicts of interest to report.
• SyllabusMaterial on extravasation
• “Grab and go” section of clinically relevant articles
– Summary sheet on carboxypeptidase G2• Recent relevant publications• How to access medication
J Med Tox 2008;4(2):132-140
![Page 96: Toxicological Emergencies in the Oncology Patient: Antidotal Therapies 2008 ACMT Pre-Meeting Symposium Rama B. Rao, MD NYCPCC NYPH-Weill-Cornell Medical.](https://reader030.fdocuments.in/reader030/viewer/2022032707/56649e395503460f94b2b501/html5/thumbnails/96.jpg)
Acknowledgements
• Major Urban Cancer Centers in NYC
• Lisa Schulmeister, RN
• Scott Ely, MD, MPH
• Faculty, NYC Poison Control Center
• ACMT